Navigation Links
Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares

TEL AVIV, Israel, October 12 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit") announces today that on October 9 ,2009 it sold a total of 4,794,292 ordinary shares of it subsidiary, Plaza Centers N.V., (LSE: PLAZ) (WSE: PLAZ/PLAZACNTR) ("Plaza"), to a number of Polish institutional investors. The aggregate consideration for the shares sold by Elbit is approximately GBP6.7 million (approximately $10.6 million) representing a price of 6.5 Polish Zlotys ("PLN") per share (approximately GBP1.41 ), compared to the Warsaw Stock Exchange closing price on October 9, 2009 of 6.6 PLN per share (approximately GBP1.43 ). These shares were originally purchased by Elbit for a total consideration of GBP2.9 million (approximately $4.6 million), representing an average price of GBP0.61 per share. As result of this transaction, Elbit will generate a net cash flow of approximately GBP3.8 million (approximately $ 6.0 million).

In addition, Plaza has also notified today that it has sold 14,500,000 of its shares for a total aggregate consideration of approximately GBP20.5 million (approximately $32.5 million) representing a price of 6.5 PLN per share (approximately GBP1.41) to such investors. These shares were originally repurchased by Plaza for a total consideration of GBP7.7 million (approximately $ 12.2 million), representing an average price of GBP0.53 per share. As a result of this transaction, Plaza will generate a net cash flow of approximately GBP12.8 million (approximately $20.3 million).

The said shares were originally purchased within the framework of Plaza's repurchase shares program announced on October 20, 2008 which was executed between October 2008 and January 2009.

Following these transactions Elbit currently owns approximately 68.3% of Plaza share capital.

About Elbit Imaging Ltd.

The Activities of Elbit Imaging Ltd. are divided into the following principal fields: (i) Shopping and Entertainment Centers - Initiation, construction, operation, management and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India; (ii) Hotels - Hotel ownership, operation, management and sale, primarily in major European cities; (iii) Image Guided Treatment - Investments in the research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment; (vi) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real projects, predominantly residential, located in Eastern Europe and in India; and (v) Other Activities - (a) The distribution and marketing of fashion apparel and accessories in Israel; (b) venture capital investments; and (c) investments in hospitals, and farm and dairy plants in India, which are in preliminary stages.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2008, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2008, under the caption "Risk Factors."

    For Further Information:

    Company Contact:
    Shimon Yitzhaki, President
    Elbit Imaging Ltd.

    Dudi Machluf, CFO
    Elbit Imaging Ltd.

    Investor Contact:
    Mor Dagan
    Investor Relations

SOURCE Elbit Imaging Ltd.

SOURCE Elbit Imaging Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
2. Breast-Specific Gamma Imaging Proves Cost-Effective for Pre-Surgical Planning of Patients with Known Cancer Diagnosis
3. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
4. Amnis Begins Shipment of New ImageStreamX Imaging Flow Cytometers
5. SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental Disorders
6. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
7. Envisionier Announces the Launch of the endogo(R) HD, a Mobile Medical Imaging Platform for Capturing, Storing, and Sharing Endoscopic Multimedia
8. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
9. CRi Oosight Imaging System a Key to Breakthrough Gene Replacement Method With Potential to Prevent Inherited Mitochondrial Diseases
10. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
11. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
Post Your Comments:
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... York , 24. November 2015 /PRNewswire/ ... Avery Breathing Pacemaker Systems, ist erfreut, die ... Clinical Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch ... solutions involving adult stem cell therapies to patients with chronic degenerative medical conditions. ... as a Registered Trademark (RTM). , Organizations are required to hold a registered ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA , ... now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. This ... cutting tools, such as the scalpel and high-speed drill, which can both cause patients ...
(Date:11/24/2015)... Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... explored the different restrictions and variables that determine which patients are or are not ... those patients that have a BMI over 40, are more than 100 pounds overweight, ...
(Date:11/24/2015)... City, UT (PRWEB) , ... November 24, 2015 , ... ... Forbes Magazine. For a business, it is critical that the first impression be positive ... business, they are not likely to buy anything or want to return. They will ...
Breaking Medicine News(10 mins):